STTR Phase I: Novel Production Platform for Synthesis of Toxic Enzymes

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$150,000.00
Award Year:
2008
Program:
STTR
Phase:
Phase I
Contract:
0740643
Award Id:
88487
Agency Tracking Number:
0740643
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
13328 Manor Stone Drive, Germantown, MD, 20874
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
608276296
Principal Investigator:
Aprile Pilon
DPhil
(301) 452-2899
apilon@apcbio.com
Business Contact:
Aprile Pilon
DPhil
(301) 452-2899
apilon@apcbio.com
Research Institute:
Princeton University
David Wood
E-Quad
Princeton, NJ, 8544
(301) 452-2899
Nonprofit college or university
Abstract
This Small Business Technology Transfer Phase I research develops a novel bioprocess platform for the synthesis of toxic enzymes as inactive pro-enzymes in bacteria that can subsequently be activated via simple pH and/or temperature shifts. Recombinant enzymes for industrial synthetic applications or pharmacologic replacement therapies can be very difficult and expensive to produce in large quantities in an active form because they are toxic to the host, self-inactivate, or both. Numerous proteases, digestive enzymes, and cross-linking enzymes that break down or build up macromolecular complexes with high commercial potential are all but impossible to isolate in active form. The company proposes to use the catalytic core of the human transglutaminase 1 enzyme (TG1) to prove the concept. This research could have a direct impact on patients suffering from a severe form of ?scaly skin? disease, known as lamellar icthyosis, who have a defect in their TG1 gene. The broader impacts of this research are development of novel biomaterials and/or processes for several industries, including biotechnology, food processing, cosmetics and skin care (non-pharmacologic), detergents, and possibly waste remediation. Recombinant transglutaminases will specifically enable the development of novel types of biopolymers and materials. The research with TG1 could have a broader impact in the biomedical industry because it may lead to the development of a TG1-based ?liquid bandage? product for use in treatment of wounds, burns and cosmetic/reconstructive surgeries.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government